From 11:00 pm to 12:00 pm EST ( 8:00 pm to 9:00 pm PST ) on January 6th, the website will be under maintenance. We are sorry for the inconvenience. Please arrange your schedule properly.
[5-(2-Thienyl)-3-isoxazolyl]methanol (Compound D) is an AgrA-DNA binding inhibitor. [5-(2-Thienyl)-3-isoxazolyl]methanol can be used for S.aureus infection research .
Lauric acid is a middle chain-free fatty acid with strong bactericidal properties. The EC50s for P. acnes, S.aureus, S. epidermidis, are 2, 6, 4 μg/mL, respectively .
Sortase A, S. aureus (SrtA), a transpeptidase enzyme is present in many Gram-positive bacteria and helps in the recruitment of the cell surface proteins. Sortase A, S. aureus plays an important part in ligation of various molecules on the cell surfaces .
Secologanin dimethyl acetal (Compound Ⅱ) is an iridoid glucoside that can be isolated from Pterocephalus perennis. Secologanin dimethyl acetal shows antimicrobial activity against S.aureus and S.epidermidi .
Lauric acid- 13C is the 13C labeled Lauric acid. Lauric acid is a middle chain-free fatty acid with strong bactericidal properties. The EC50s for P. acnes, S.aureus, S. epidermidis, are 2, 6, 4 μg/mL, respectively.
Lauric acid-d33 is the deuterium labeled Lauric acid. Lauric acid is a middle chain-free fatty acid with strong bactericidal properties. The EC50s for P. acnes, S.aureus, S. epidermidis, are 2, 6, 4 μg/mL, respectively.
Lauric acid-d233 is the deuterium labeled Lauric acid. Lauric acid is a middle chain-free fatty acid with strong bactericidal properties. The EC50s for P. acnes, S.aureus, S. epidermidis, are 2, 6, 4 μg/mL, respectively.
Lauric acid-d2 is the deuterium labeled Lauric acid. Lauric acid is a middle chain-free fatty acid with strong bactericidal properties. The EC50s for P. acnes, S.aureus, S. epidermidis, are 2, 6, 4 μg/mL, respectively.
Lauric acid-d5 is the deuterium labeled Lauric acid. Lauric acid is a middle chain-free fatty acid with strong bactericidal properties. The EC50s for P. acnes, S.aureus, S. epidermidis, are 2, 6, 4 μg/mL, respectively.
Tenuigenin is a major active component isolated from the root of the Chinese herb Polygala tenuifolia. Tenuigenin protects against S.aureus-induced pneumonia by inhibiting NF-κB activation. Tenuigenin has anti-inflammatory effect .
XT-1 is an antimicrobial peptide derived from skin secretions of Xenopus tropicalis. XT-1 has strong activity against S.aureus, E.coli and C.albicans, the vaule of MIC are 5, 6, 50 μM , respectively .
Lauric acid (Standard) is the analytical standard of Lauric acid. This product is intended for research and analytical applications. Lauric acid is a middle chain-free fatty acid with strong bactericidal properties. The EC50s for P. acnes, S.aureus, S. epidermidis, are 2, 6, 4 μg/mL, respectively.
Lauric acid- 13C-1 is the deuterium labeled Lauric acid. Lauric acid is a middle chain-free fatty acid with strong bactericidal properties. The EC50s for P. acnes, S.aureus, S. epidermidis, are 2, 6, 4 μg/mL, respectively[1].
MCF is an antimicrobial peptide derived from bee venom. MCF has activity against E.coli W 160-37, S.aureus 8530 and B.subtilis, the MIC values are 35-45 μg/ml, 25-35 μg/ml and 15-25 μg/ml .
Antibacterial agent 113 (compound 3) is a potent antibacterial agent. Antibacterial agent 113 shows antibacterial activity against P.aeruginosa, S.mutans, B.subtilis, E.coli, E.faecalis, S.typhimuriumand, and S.aureus microorganisms, with MIC values all of 156.25 μM .
VU0420373 is a potent heme sensor system (HssRS) activator with an EC50 of 10.7 μM and a pEC50 of 4.97. VU0420373 induces heme biosynthesis, and is toxic to fermenting S. aureus .
Bovine tracheal antimicrobial peptide is a kind of comes from the tracheal mucosa of antimicrobial peptides. Bovine tracheal antimicrobial peptide has activity against E.coli D31, K.pneumoniae 13883, S.aureus 25923, P.aeruginosa 27853 and C.albicans 14053, MIC value 12-25, 12-25, 25-50, 25-50, 6-12 μg/ml, respectively .
Platensimycin is an antibiotic produced by S. platensis that inhibits gram-positive bacteria by selectively inhibiting cellular lipid biosynthesis (IC50=0.1 μM). Platensimycin targets the β-ketoacyl-acyl-carrier-protein synthase I/II, FabF/B, an enzyme that participates in the biosynthesis of fatty acids (IC50s=48 nM and 160 nM for S.aureus and E.coli enzymes, respectively). Platensimycin is a promising agent for overcoming antibiotic resistance.
PK150, an analogue of Sorafenib, shows oral bioavailability and antibacterial activity against several pathogenic strains at submicromolar concentrations. PK150 inhibits Gram-positive Methicillin-sensitive S. aureus (MSSA), Methicillin-resistant S. aureus (MRSA), Vancomycin intermediate S. aureus (VISA) with MICs of 0.3, 0.3-1, 0.3 µM, respectively .
ASP-1 is a strong antistaphylococcal peptide with minimum inhibitory concentrations (MICs) of the purified peptide against S. aureus and methicillin-resistant S. aureus (MRSA) ranged from 2 μg/mL to 64 μg/mL .
Targocil functions as a bacteriostatic inhibitor of wall teichoic acid (WTA) biosynthesis which can inhibit the growth of methicillin-susceptible S. aureus (MSSA) and methicillin-resistant S. aureus (MRSA) with MIC90s of 2 μg/ mL for both MRSA and MSSA.
SYNV-cyclo(CGGYF) is a Staphylococcus hominis (S. hominis) C5 autoinducing peptide. SYNV-cyclo(CGGYF) inhibits S. aureus activity. SYNV-cyclo(CGGYF) has the potential for the research of S. aureus-mediated epithelial damage and inflammation .
GW779439X is a pyrazolopyridazine identified in an inhibitor of the S. aureus PASTA kinase Stk1. GW779439X potentiates the activity of β-lactam antibiotics against various MRSA and MSSA isolates, some even crossing the breakpoint from resistant to sensitive. GW779439X is an AURKA inhibitor and induces apoptosis by the caspases 3/7 pathway . MRSA:methicillin-resistant S. aureus; MSSA: methicillin-sensitive S. aureus
Omodenbamab is an anti-SpA (Staphylococcal protein A) human monoclonal antibody with a KD value of 0.0467 nM. Omodenbamab circumvents a key S. aureus evasion mechanism by targeting the cell wall moiety Protein A (SpA). Omodenbamab can be used in research of S. aureus bloodstream infection .
Lysionotin is a flavonoid isolated from Gesneriaceae family. Lysionotin efficiently inhibit α-Toxin (a pore-forming protein) expression and shows significant protection against S. aureus in vitro and in vivo. Lysionotin has the potential for the treatment of S. aureus induced pneumonia .
SYNV-cyclo(CGGYF) TFA is a Staphylococcus hominis (S. hominis) C5 autoinducing peptide. SYNV-cyclo(CGGYF) TFA inhibits S. aureus activity. SYNV-cyclo(CGGYF) TFA has the potential for the research of S. aureus-mediated epithelial damage and inflammation .
Antibacterial agent 19 (compound 8) is a potent antibacterial agent. Antibacterial agent 19 has antibacterial activity against K. pneumoniae, (M-R)S. aureus and (M-R,V-R)S. aureus with MIC values of 0.022, 0.022 and 0.045 mg/mL, respectively .
Rifaquizinone (CBR-2092) is a Rifamycin-Quinolone Hybrid Antibiotic. Rifaquizinone inhibits wild-type S. aureus RNA polymerase with an IC50 of 34 nM. Rifaquizinone is effective against S. aureus infections, with MICs ranged from 0.008 to 0.5 μg/mL for 300 clinical isolates of staphylococci and streptococci .
Antibacterial agent 98 (compound g37) is a potent and orally active antibacterial agent. Antibacterial agent 98 inhibits the ATPase activity of Gyrase B and impairs Staphylococcus aureus (S. aureus ) DNA supercoiling. Antibacterial agent 98 shows antibacterial activity and not induce resistance development of MRSA (methicillin-resistant S. aureus) .
Lugdunin is an antibiotic peptide. Lugdunin inhibits bacteria by dissipating their membrane potential. Lugdunin is active against Gram-positive bacteria, such as S. aureus, and reduces S. aureus skin and nasal colonization. Lugdunin induces LL-37 and CXCL8/MIP-2 in human keratinocytes and mouse skin .
Anti-MRSA agent 7 (Compound 12) is a potent antibacterial agent. Anti-MRSA agent 7 inhibits S. aureus DNA gyrase, E. coli DNA gyrase, S. aureus topo IV and E. coli topo IV with IC50s of 0.185, 0.365, 0.341 and 0.059 μM, respectively .
Synthalin A sulfate is a biguanylated diamine with antibacterial and hypoglycemic properties. Synthalin A sulfate against S. aureus with a MIC of 64 μg/mL .
AM8191 is an orally active bactericidal and selectively inhibits DNA synthesis and Staphylococcus aureus gyrase (IC50=1.02 μM) and topo IV (IC50=10.4 μM). AM8191 inhibits S. aureus MSSA (MIC=0.02 μg/mL) and S. aureus MRSA (MIC=0.06 μg/mL) .
Polistes mastoparan is an antimicrobial peptide. Polistes mastoparan increases S. aureus cell K + efflux and inhibits cell viability with EC50 of 5 μM .
Corianin is a sesquiterpene lactone that can be isolated from the fruits of Coriaria ruscifolia. Corianin shows antibacterial activity against S. aureus and S. epidermis .
Tosatoxumab (AR-301; KBSA301) is a human immunoglobulin G1 monoclonal antibody that specifically neutralizes alpha-toxin (alpha-hemolysin; Hla) of S. aureus. Tosatoxumab binds to an N-terminal epitope of alpha-toxin, thereby preventing functional toxin pore oligomerisation. Tosatoxumab has the potential for passive immunotherapy in the S. aureus pneumonia as an adjunctive therapy to standard antibiotic agent .
Pagibaximab is a chimeric IgG1 antibody recognizing the surface component lipoteichoic acid of S. aureus and S. epidermidis. Pagibaximab can be used to prevent staphylococcal sepsis .
(3R)-7,4’-Dihydrohomoisoflavanone is a natural product with antibacterial activities against S. aureus and methicillin-resistant Staphylococcus aureus (MRSA) .
Stearyl glycyrrhetinate, a major component in licorice extract, has a MIC against S. aureus strains of more than 256 mg/L. Stearyl glycyrrhetinate has antibacterial effects .
Desacetylcephapirin sodium (Deacetylcephapirin sodium) is an active metabolite of Cephapirin (HY-A0153A). Desacetylcephapirin sodium has antimicrobial against S. aureus and coagulase-negative staphylococci mastitis pathogen .
Thiolopyrrolone A (compound 1) exhibits antibacterial activities against BCG, M. tuberculosis and S. aureus with minimum inhibitory concentrations (MIC) of 10, 10 and 100 μg/mL, respectively .
Pisiferic acid is an antibacterial agent with inhibitory activity against Gram-negative/positive bacteria such as P. vulgaris, S. aureus and B. subtilis. Pisiferic acid can be used to study bacterial infections .
AFN-1252 is an orally active and selective inhibitor of FabI, an essential enzyme in fatty acid biosynthesis in Staphylococcus spp. AFN-1252 exhibits exquisite and highly selective activity against Staphylococcus spp. AFN-1252 exhibits typical MIC90 values of ⩽0.015 μg/ml against diverse clinical isolates of S. aureus. AFN-1252 is efficacious in a mouse model of septicemia providing 100% protection from an otherwise lethal peritoneal infection of S. aureus Smith .
MUT056399 (Fab-001) is a highly potent inhibitor of the FabI enzyme of both S. aureus and E. coli with 50% inhibitory concentration IC50s of 12 nM and 58 nM, respectively.
Ianthelliformisamine B diTFA is a bromotyrosine-derived antibacterial agent. Ianthelliformisamine B diTFA is against E. coli and S. aureus strains with MICs of 14.5 μM and 144.7 μM .
Antibacterial agent 87 (Compound 4h) is a potent antibacterial agent with MIC values of 0.125, 0.0625 and 0.0625 μg/mL against MRSA, MRSE and S. aureus, respectively .
Maximin 41 is an antimicrobial peptide. Maximin 41 has antibacterial activity against S. aureus (MIC: 75 μg/mL). Maximin 41 has hemolytic activities against human red cells .
Antimicrobial photosensitizer-1 is a promising candidate as the antimicrobial photosensitizer for combating pathogenic microorganism infections. Antimicrobial photosensitizer-1 exhibits an impressive antimicrobial efficacy in S. aureus-infected mice wounds .
Maximin 42 is an antimicrobial peptide. Maximin 42 has antibacterial activity against S. aureus (MIC: 37.5 μg/mL). Maximin 42 has hemolytic activities against human red cells .
Maximin 77 is an antimicrobial peptide. Maximin 77 has antibacterial activity against S. aureus (MIC: 18.8 μg/mL). Maximin 77 has hemolytic activities against human red cells .
Maximin 49 is an antimicrobial peptide. Maximin 49 has antibacterial activity against S. aureus (MIC: 18.8 μg/mL). Maximin 49 has hemolytic activities against human and rabbit red cells .
Penicillin V Potassium (Phenoxymethylpenicillin potassium salt) is an orally active antibiotic. Penicillin V Potassium inhibits the growth of Streptococci, C. difficile and S. aureus. Penicillin V Potassium can be used for the research of otitis, sinusitis, pharyngitis and tonsillitis .
Antibacterial agent 97 (hit compound) is a potent antibacterial agent. Antibacterial agent 97 shows antibacterial activities with MIC of 16 and 16 µg/mL for Escherichia coli (E. coli) and Staphylococcus aureus (S. aureus), respectively .
Melimine is a hybrid antimicrobial peptide of Melittin (HY-P0233) and Protamine. Melimine is active against P. aeruginosa and S. aureus. Melimine has broad spectrum activity against bacteria, fungi and protozoa .
Im5, an antimicrobial peptide, has antibacterial (MIC: 10, 2.5-5, 0.5-1 μM for E. coli, S. aureus, B. subtilis respectively) and hemolytic activity (EC50: 28 μM) .
GP-2B is an antimicrobial peptide. GP-2B shows antibacterial activity against Gram-positive strain (MIC: 8-128 μg/mL for S. aureus and Enterococcus faecalis) .
Antibacterial agent 164 (compound 2a) is an antibacterial and antibiofilm agent. Antibacterial agent 164 inhibits S. aureus and B. subtilis (MIC of 0.09 mM), and also exhibits strong anti-B. Subtilis biofilm formation .
Lividomycin A is a broad-spectrum aminoglycoside antibiotic. Lividomycin A shows antimicrobial activity. Lividomycin A shows a positive protecting effect for the experimental infections in mice with several bacteria such as S. aureus, P. aeruginosa, Klebsiella pneumoniae and Escherichia coli .
2,5-Dihydroxybenzaldehyde (Gentisaldehyde) is a naturally occurring antimicrobial that inhibits the growth of Mycobacterium avium subsp. paratuberculosis. 2,5-Dihydroxybenzaldehyde is active against S. aureus strains with a MIC50 of 500 mg/L .
4-Chloroguaiaco (4-Chloro-2-methoxyphenol) is a phenol derivative, with antimicrobial activity. 4-Chloroguaiaco shows inhibition against S. aureus and E. coli with MICs of both 110 μg/mL .
DHFR-IN-17 (compound j9) is an oral active SaDHFR inhibitor with the IC50 of 0.97 nM. DHFR-IN-17 shows antibacterial activity against S. aureus with the minimum inhibitory concentration of 0.031 μg/mL .
(-)-Corynoxidine is an acetylcholinesterase inhibitor with an IC50 value of 89.0 μM, isolated from the aerial parts of Corydalis speciosa .
(-)-Corynoxidine exhibits antibacterial activities against Staphylococcus aureus and methicillin-resistant S. aureus strains in different degrees .
Voxvoganan (LTX-109), a topical antimicrobial, is highly effective against S. aureus with a MIC range of 2 to 4 μg/mL. Voxvoganan can be used for the research of bacterial skin infections, fungal infections and nasal decolonisation of MRSA .
Angustifoline, an alkaloid, can be isolated from Lupinus angustifolius L. alkaloid extract. Angustifoline exhibits antimicrobial activity. Angustifoline could have bacteriostatic effects against S. aureus, B. subtilis, E. coli, P. aeruginosa and B. thuringiensis .
Voxvoganan (LTX-109) trihydrochloride, a topical antimicrobial, is highly effective against S. aureus with a MIC range of 2 to 4 μg/mL. Voxvoganan trihydrochloride can be used for the research of bacterial skin infections, fungal infections and nasal decolonisation of MRSA .
cPcAMP1/26 is an antimicrobial peptide. cPcAMP1/26 effectively kills A.hydrophila and S. aureus. cPcAMP1/26 induces depolarization of the bacterial plasma membrane, and increases intracellular ROS levels .
PP102 is an antimicrobial peptide is active against gram-positive B. subtilis (MIC: 25 uM), S. aureus (MIC: 13.3 uM), S. lutea (MIC: 63 uM), and B. pumilu (MIC: 23 uM) .
FASN-IN-6 (compound 44) is a potent fatty acid biosynthesis (FAB) inhibitor. FASN-IN-6 is an antibacterial agent with MICs of 1 μg/mL and 4 μg/mL for S. aureus ATCC 25923 and E. faecalis ATCC 29212, respectively .
Antibacterial agent 207 (Compound Ru1) has antibacterial activity against S. aureus (MIC: 1 μg/mL), and low resistance frequencies. Antibacterial agent 207 destroys the bacterial cell membrane, promote production of ROS in bacteria .
Antibacterial agent 88 (Compound 5h) is a potent antibacterial agent with MIC values of both ≤0.0156 μg/mL against MRSA, MRSE and S. aureus. Antibacterial agent 88 also inhibits B. subtilis with an MIC of 4 μg/mL .
Angustifoline hydrochloride, an alkaloid, can be isolated from Lupinus angustifolius L. alkaloid extract. Angustifoline hydrochloride exhibits antimicrobial activity. Angustifoline hydrochloride could have bacteriostatic effects against S. aureus, B. subtilis, E. coli, P. aeruginosa and B. thuringiensis .
Iclaprim-d6 (AR-100-d6) is the deuterium labeled Iclaprim. Iclaprim is a new selective bacterial Dihydrofolate inhibitor, which can inhibit the growth of S. aureus (MRSA) with an MIC90 of 0.06 μg/mL.
Antibacterial synergist 2 (compound 27) is a biofilm inhibitor. Antibacterial synergist 2 shows inhibitory effects to S. enterica, S. aureus, P. aeruginosa and C. albicans. Antibacterial synergist 2 can be used for the research related to biofilm-forming pathogens .
Antibacterial agent 143 (Compound 5a) is an antibacterial agent with MICs of 25, 25, 50 and 50 μg/mL against B. subtilis ATCC6633, S. aureus ATCC6538, P. aeruginosa ATCC13525 and E. coli ATCC35218, respectively .
Continentalic acid from Aralia continentalis has minimum inhibitory concentrations (MICs) of approximately 8-16 µg/mL against S. aureus, including the Methicillin (HY-121544) susceptible Staphylococcus aureus (MSSA) and Methicillin-resistant Staphylococcus aureus (MRSA) standard strains .
Aurein 2.6 is an antibiotic antimicrobial peptide. Aurein 2.6 is active against Gram-positive bacterial (MIC: 25, 25, 30, 25, 30 μM for M. luteus, S. aureus, S. epidermis, S. mutans, B. subtilis) .
Aurein 3.1 is an antibiotic antimicrobial peptide. Aurein 2.6 is active against Gram-positive bacterial (MIC: 80, 50, 50, 50, 50 μM for M. luteus, S. aureus, S. epidermis, S. mutans, B. subtilis) .
Distinctin is an antimicrobial peptide. Distinctin can be isolated from frog skin. Distinctin has antibacterial activity against E. faecalis, P. aeruginosa, S. aureus and E. coli (MIC: 14.5, 28.0, 28.0, 14.5 μM) .
17(R)-Resolvin D4 (17(R)-RvD4) is the R-enantiomer of Resolvin D4. Resolvin D4 (RvD4), a specialized proresolving mediator, can be produced in bioactive levels during S. aureus infection .
BPH-1358 (NSC50460) is a potent human farnesyl diphosphate synthase (FPPS) and undecaprenyl diphosphate synthase (UPPS) inhibitor with IC50s of 1.8 μM and 110 nM, respectively, and is active against S. aureus in vitro (MIC ~250 ng/mL) .
Antibacterial agent 86 (Compound A11) is the most active and displays bacteriostatic activities against methicillin-resistant S. aureus, with MIC values as low as 0.00191 μg/mL, which is 162 and 32 times lower than that of the marketed antibiotics tiamulin and retapamulin, respectively .
Antibacterial agent 81 is a DNA transcription inhibitor. Antibacterial agent 81 inhibits S. aureus USA300 and M. smegmatis ATCC14468 with MIC values of 12.5 and 7.8 μM, respectively. Antibacterial agent 81 can be used for the research of infection .
8-Hydroxy-9,10-diisobutyryloxythymol is a natural monoterpenoid with antibacterial properties. 8-Hydroxy-9,10-diisobutyryloxythymol against S. aureus, S. flexneri, and S. paratyphi-B with MIC values of 6.25 μg/mL .
Maximin 45 is an antimicrobial peptide. Maximin 41 has antibacterial activity against S. aureus, E. coli, B. subtilis (MIC: 4.7, 9.4, 75 μg/mL). Maximin 45 has hemolytic activities against human and rabbit red cells .
Cloxacillin sodium monohydrate is an orally active antibacterial agent and β-lactamase inhibitor with an IC50 of 0.04 µM. Cloxacillin sodium monohydrate can suppress the S. aureus-induced inflammatory response by inhibiting the activation of MAPKs, NF-кB and NLRP3-related proteins .
Methicillin sodium salt (Meticillin sodium) is a β-lactam, semi-synthetic antibiotic related to penicillin antibiotic. Methicillin sodium salt inhibits penicillin-binding proteins involved in the synthesis of peptidoglycan. Methicillin sodium salt inhibits S. aureus with a MIC value of 2.1 μg/mL. Methicillin sodium salt can be used for the research of inflammation .
Zoliflodacin (ETX0914;AZD0914) is a novel spiropyrimidinetrione bacterial DNA gyrase/topoisomerase inhibitor. Zoliflodacin has potent in vitro antibacterial activity against Gram-positive and Gram-negative organisms, including S. aureus with the MIC90 of 0.25 μg/mL.
Cloxacillin sodium is an orally active antibacterial agent and β-lactamase inhibitor with an IC50 of 0.04 µM. Cloxacillin sodium can suppress the S. aureus-induced inflammatory response by inhibiting the activation of MAPKs, NF-кB and NLRP3-related proteins .
Penicillin V- 13C6 (potassium) is the 13C6 labeled Penicillin V (potassium). Penicillin V Potassium (Phenoxymethylpenicillin potassium salt) is an orally active antibiotic. Penicillin V Potassium inhibits the growth of Streptococci, C. difficile and S. aureus. Penicillin V Potassium can be used for the research of otitis, sinusitis, pharyngitis and tonsillitis.
Cloxacillin is an orally active antibacterial agent and β-lactamase inhibitor with an IC50 of 0.04 µM. Cloxacillin can suppress the S. aureus-induced inflammatory response by inhibiting the activation of MAPKs, NF-кB and NLRP3-related proteins .
Epitaraxerol (compound 6) is a natural product isolated from the leaves of E. neriifolia. Epitaraxerol shows moderate antifungal activity against C. albicans and low antimicrobial activity against T. mentagrophytes, A. niger, S. aureus, E. coli, P. aeruginosa, and B. subtilis .
Maximin 78 is an antimicrobial peptide. Maximin 78 has antibacterial activity against C. albicans, S. aureus, B. subtilis (MIC: 37.5, 4.7, 37.5 μg/mL). Maximin 78 has hemolytic activities against human and rabbit red cells .
LtaS-IN-2 (compound 13) is a inhibitor of LTA synthesis, and shows antibacterial activity against S. aureus and S. epidermidis, with the MIC90 of 0.5 μg/mL and 1 μg/mL, respectively. LtaS-IN-2 is a derivative of LtaS-IN-1 (HY-135813) .
TLN-58 is an antimicrobial peptide. TLN-58 has antibacterial activity against S. aureus, S. epidermidis, and group A Streptococcus. TLN-58 also induces inflammatory cytokine mRNAs upregulation in normal human keratinocytes and NCL-SG3 cells .
BPH-1358 mesylate (NSC50460 mesylate) is a potent human farnesyl diphosphate synthase (FPPS) and undecaprenyl diphosphate synthase (UPPS) inhibitor with IC50s of 1.8 μM and 110 nM, respectively. BPH-1358 mesylate is active against S. aureus in vitro (MIC ~250 ng/mL) .
MC-Val-Cit-PAB-dimethylDNA31 is a agent-linker conjugate for ADC with potent antitumor activity by using dimethylDNA31, linked via the ADC linker MC-Val-Cit-PAB. DimethylDNA31 has effective bactericidal activity against persisters and stationary-phase S. aureus.
LA-Bac8c is a Lipoic acid modified antimicrobial peptide with enhanced antimicrobial properties. LA-Bac8c inhibits S. aureus, MRSA, S. epidermidis, E. coli, and P. aeruginosa with MICs of 1, 4, 8, 8, and 8 μg/mL .
Maximin H39 is an antimicrobial peptide. MaximinH39 has antibacterial activity against C. albicans, S. aureus, B. subtilis (MIC: 9.4, 9.4, 18.8 μg/mL). Maximin H39 has hemolytic activities against human and rabbit red cells .
BPH-1358 free base (NSC50460 free base) is a potent human farnesyl diphosphate synthase (FPPS) and undecaprenyl diphosphate synthase (UPPS) inhibitor with IC50s of 1.8 μM and 110 nM, respectively, and is active against S. aureus in vitro (MIC ~250 ng/mL) .
MDP1, a Melittin-derived peptide, alters the integrity of both Gram-positive and Gram-negative bacterial membranes and kills the bacteria via membrane damages. MDP1 has a high-antibacterial activity against multidrug resistant (MDR) and reference strains of S. aureus, E. coli, and P. aeruginosa .
MDP1 acetate, a Melittin-derived peptide, alters the integrity of both Gram-positive and Gram-negative bacterial membranes and kills the bacteria via membrane damages. MDP1 acetate has a high-antibacterial activity against multidrug resistant (MDR) and reference strains of S. aureus, E. coli, and P. aeruginosa .
Levonadifloxacin ((S)-(-)-Nadifloxacin; WCK 771) is a broad-spectrum anti-staphylococcal agent. Levonadifloxacin shows antibacterial activity against Methicillin (HY-121544)-susceptible Staphylococcus aureus (MSSA) and Methicillin-resistant S. aureus (MRSA) strains, with a reduction of which phagocytized in THP-1 monocytes .
Amphomycin is a lipopeptide antibiotic that inhibits peptidoglycan synthesis and blocks cell wall development. Amphomycin exhibits potent antibacterial activities against methicillin-resistant S. aureus (MRSA), vancomycin-resistant enterococci (VRE), penicillin-gentamicin-erythromycin-resistant S. pneumonia, and linezolid-quinupristin-dalfopristin-resistant enterococci .
Maximin 68 is an antimicrobial peptide. Maximin 68 has antibacterial activity against C. albicans, S. aureus, E. coli, B. subtilis (MIC: 18.8, 9.4, 37.5, 9.4 μg/mL). Maximin 68 has hemolytic activities against human and rabbit red cells .
Antibacterial agent 175 (compound Y40), a ML346 (HY-18669) analog, is a Sortase A (SrtA) inhibitor. Antibacterial agent 175 shows inhibitory activity on Staphylococcus aureus SrtA and shows inhibitory effects on biofilm formation. Antibacterial agent 175 is an antivirulence agent against S. aureus infections .
Antitubercular agent-45 (Compound 5g) is an antifungal and antitubercular agent. Antitubercular agent-45 inhibits S. aureus, MRSA, B. subtilis, E. coli, C. albicans with MIC values of 6.4, 10.8, 6.1, 8.4 , 8.1 μM respectively .
Clinafloxacin (AM 1091) is a potent and broad-spectrum fluoroquinolone antibiotic, has inhibitory activity against gram-positive, gram-negative bacterias, and anaerobic pathogens in vitro . Clinafloxacin is against DNA gyrase and topoisomerase IVof S. aureus with IC50 values of 0.92 µg/ml and 1.62 µg/ml, respectively .
Clinafloxacin hydrochloride (AM 1091 hydrochloride) is a potent and broad-spectrum fluoroquinolone antibiotic, has inhibitory activity against gram-positive, gram-negative bacterias, and anaerobic pathogens in vitro . Clinafloxacin hydrochloride is against DNA gyrase and topoisomerase IVof S. aureus with IC50 values of 0.92 µg/ml and 1.62 µg/ml, respectively .
CysHHC10 is a synthetic antimicrobial peptide (AMP), and exhibits strong anti-microbial properties against both Gram-positive and Gram-negative bacteria. The MIC values of CysHHC10 against E. coli, P. aeruginosa, S. aureus and S. epidermidis are 10.1 mM, 20.2 mM, 2.5 mM and 1.3 mM, respectively .
PP113 is an antimicrobial peptide is active against Gram-negative and Gram-positive bacteria, E.coli (MIC: 73.3 uM), B. subtilis (MIC: 23.3 uM), S. aureus (MIC: 13 uM), S. lutea (MIC: 16.7 uM), and B. pumilu (MIC: 23.3 uM) .
Galbinic acid (α-Acetylsalazinic acid), a lichen acid, shows antibacterial activities against the Gram-positive bacteria B. cereus, B. subtilis, and S. aureus (MICs=62.5, 62.5, 250 μg/ml, respectively). Galbinic acid inhibits the Gram-negative bacterium E. coli (MIC=125 μg/ml) .
Antibacterial agent 109 (Compound C-2) is a potent antibacterial agent against both gram-positive and gram negative bacteria, and non-mutagenic. Antibacterial agent 109 inhibits protein synthesis by blocking the extension of new peptide chains .
Penicillin V-d5 (Phenoxymethylpenicillin-d5) is the deuterium labeled Penicillin V. Penicillin V (Phenoxymethylpenicillin) is an orally active antibiotic. Penicillin V inhibits the growth of Streptococci, C. difficile and S. aureus. Penicillin V can be used for the research of otitis, sinusitis, pharyngitis and tonsillitis[1][2][3][4].
Thiocillin I is a thiopeptide antibiotic and has in vitro antibacterial activity against Gram-positive bacterial strains. The MIC values of Thiocillin I against S. aureus 1974149, E. faecalis 1674621, B. subtilis ATCC 6633 and S. pyogenes 1744264 are 2 μg/mL, 0.5 μg/mL, 4 μg/mL and 0.5 μg/mL, respectively .
CysHHC10 TFA is a synthetic antimicrobial peptide (AMP), and exhibits strong anti-microbial properties against both Gram-positive and Gram-negative bacteria. The MIC values of CysHHC10 TFA against E. coli, P. aeruginosa, S. aureus and S. epidermidis are 10.1 mM, 20.2 mM, 2.5 mM and 1.3 mM, respectively .
AN0128 is a boron-containing antibacterial and anti-inflammatory agent. AN0128 against S. aureus, S. epidermidis, P. acnes, B. subtilis with minimum inhibitory concentration (MIC) values of 1, 0.5, 0.3, 1 μg/mL. AN0128 can be used for the research of periodontal disease and cutaneous diseases .
Penicillin V (Potassium)-d5 is the deuterium labeled Penicillin V Potassium[1]. Penicillin V Potassium (Phenoxymethylpenicillin potassium salt) is an orally active antibiotic. Penicillin V Potassium inhibits the growth of Streptococci, C. difficile and S. aureus. Penicillin V Potassium can be used for the research of otitis, sinusitis, pharyngitis and tonsillitis[2][3][4][5].
PP13 is an antimicrobial peptide, and is active against Gram-negative and Gram-positive bacteria E.coli (MIC: 16.7 uM), B. subtilis (MIC: 13.3 uM), S. aureus (MIC: 23.3 uM), S. lutea (MIC: 8.0 uM), and B. pumilu (MIC: 9.0 uM) .
ADG-2e is a potent antibacterial agent with MICs of 16, 4, 2, and 2 μg/mL for E. coli [KCTC 1682], P. aeruginosa [KCTC 1637], B.subtilis [KCTC 3068], and S. aureus [KCTC 1621], respectively. ADG-2e shows anti-metastatic activity against breast cancer cells .
Glycol chitosan is a chitosan derivative with ethylene glycol branches. Glycol chitosan enhances membrane permeability and leadkage in Glycine max Harosoy 63W cells. Glycol chitosan is biocompatible and biodegradable . Glycol chitosan inhibits E. coli, S. aureus and S. enteritidis growths with MIC values of 4 μg/mL, 32 μg/mL and <0.5 μg/mL, respectively .
Pristinamycin, produced by Streptomyces pristinaespiralis, is an orally active streptogramin-like antibiotic consisting of two chemically unrelated components: Pristinamycin I (PI) and Pristinamycin II (PII). Pristinamycin is highly active against many antibiotic-resistant pathogens, particularly Gram-positive bacteria, including Methicillin-resistant Staphylococcus aureus (MRSA), Vancomycin-resistant S. aureus (VRSA) and Enterococcus faecium (VREF) .
1,4, 6-trihydroxy-5-methoxy-7-prenylxanthone is an antimicrobial agent that can be isolated from the genus garcinia. 1,4, 6-trihydroxy-5-methoxy-7-prenylxanthone inhibits S. aureus and B. cereus with MIC values of 128 μg/mL and 200 μg/mL, respectively .
BO-1 is a benzoate ester with antibacterial activity. BO-1 inhibits multidrug-resistant Staphylococcus aureus, and acts function synergistically with antibiotic, such as Ciprofloxacin (HY-B0356). BO-1 can reverse the resistance of antibiotic-resistant S. aureus strains, and decreases the level of inflammatory factors IL-6 and C-reactive protein in vivo in mice .
Dermaseptin-B3 inhibits the growth of Gram-positive and Gram-negative bacteria (MIC: 1.3, 2.3, 5.0, 2.6, 2.3 μM for S. aureus, P. aeruginosa, P. aeruginosa, E. (ATCC 25922), E. (54127) respectively). Dermaseptin-B3 also inhibits tumor cell proliferation .
HG2 is a fast-acting antimicrobial peptide. HG2 shows anti-biofilm and anti-inflammatory activities. HG2 is active against Gram-positive pathogens, especially against MRSA strains (MIC: 16-32?μg/mL). HG2 can bind to bacterial lipids and reduces ATP concentration in S. aureus MRSA USA300 cells .
HG4 is a fast-acting antimicrobial peptide. HG4 shows anti-biofilm and anti-inflammatory activities. HG4 is active against Gram-positive pathogens, especially against MRSA strains (MIC: 32-64?μg/mL). HG4 can bind to bacterial lipids and reduces ATP concentration in S. aureus MRSA USA300 cells .
Gatifloxacin hydrochloride (AM-1155; BMS-206584; PD135432) is a potent fluoroquinolone antibiotic with broad-spectrum antibacterial activity. Gatifloxacin hydrochloride inhibits bacterial type II topoisomerases (IC50=13.8 μg/ml for S. aureus topoisomerase IV) and E. coliDNA gyrase (IC50 = 0.109 μg/ml) . Gatifloxacin hydrochloride can be used to treat bacterial conjunctivitis in vivo.
Gatifloxacin mesylate (AM-1155; BMS-206584; PD135432) is a potent fluoroquinolone antibiotic with broad-spectrum antibacterial activity. Gatifloxacin mesylate inhibits bacterial type II topoisomerases (IC50=13.8 μg/ml for S. aureus topoisomerase IV) and E. coliDNA gyrase (IC50 = 0.109 μg/ml) . Gatifloxacin mesylate can be used to treat bacterial conjunctivitis in vivo.
Pachybasin is a major metabolite from culture broth of endophytic coelomyceteous AFKR-18 fungus. Pachybasin showes antimicrobial activities against E. coli, B. subtilis, M. luteus, S. cerevisiae, C. albicans, A. niger, and A. flavus, with MIC values of 64.0 μg/mL, and against S. aureus and F. oxysporum with MIC values of 32.0 and 16.0 μg/mL respectively .
Antibacterial agent 102 (compound 32) possesses potent in vitro and in vivo antibacterial activity, with MICs < 0.5 μg/mL in Staphylococcus aureus(S. aureus). Antibacterial agent 102 also moderately inhibits CYP3A4 with an IC50 value of 6.148 μM. Antibacterial agent 102 can reduce Methicillin-resistant Staphylococcus aureus (MRSA) load in thigh infected mice .
2',3'-Dehydrosalannol is a potent antibacterial agent. 2',3'-Dehydrosalannol shows antibacterial activity against K. pneumonia ATCC 13883, P. aeruginosa ATCC 27853, S. aureus ATCC 25922, E. coli ATCC 11775, and E. faecalis ATCC 10541, with MIC values of 0.78, 1.56, 1.56, 6.25, and 25 µg/mL, respectively .
Antibacterial agent 201 (Compound 3) is an antibacterial agent through disruption of membrane integrity. Antibacterial agent 201 inhibits proliferation of Staphylococcus aureus strain RN4220, methacillin-resistane S. aureus, Pseudomonas aeruginosa strain PA01 and Escherichia coli strain ANS1 with MIC99s of 2.0, 1, 8.1 and 2.2 μg/mL, respectively .
Floxuridine (5-Fluorouracil 2'-deoxyriboside) is a pyrimidine analog and known as an oncology antimetabolite. Floxuridine inhibits Poly(ADP-Ribose) polymerase and induces DNA damage by activating the ATM and ATR checkpoint signaling pathways in vitro. Floxuridine is a extreamly potent inhibitor for S. aureus infection and induces cell apoptosis . Floxuridine has antiviral effects against HSV and CMV .
Gatifloxacin (AM-1155; BMS-206584; PD135432) is a potent fluoroquinolone antibiotic with broad-spectrum antibacterial activity. Gatifloxacin inhibits bacterial type II topoisomerases (IC50=13.8 μg/ml for S. aureus topoisomerase IV) and E. coliDNA gyrase (IC50=0.109 μg/ml) . Gatifloxacin can be used to treat bacterial conjunctivitis in vivo.
Gatifloxacin sesquihydrate (AM-1155; BMS-206584; PD135432) is a potent fluoroquinolone antibiotic with broad-spectrum antibacterial activity. Gatifloxacin sesquihydrate inhibits bacterial type II topoisomerases (IC50=13.8 μg/ml for S. aureus topoisomerase IV) and E. coliDNA gyrase (IC50 = 0.109 μg/ml) . Gatifloxacin sesquihydrate can be used to treat bacterial conjunctivitis in vivo.
c[Arg-Arg-Arg-Arg-Nal-Nal-Nal] (Compound 9C) shows broad-spectrum activity against drug-resistant Gram-positive and Gram-negative bacteria, with MICs of 3.1, 3,1, 12.5, and 25 μg/mL for MRSA (ATCC BAA-1556), S. aureus (ATCC 29213), P. aeruginosa (ATCC 27883), and E. coli (ATCC 25922), respectively .
Anhydroerythromycin A is a degradation product of the macrolide antibiotic erythromycin. Anhydroerythromycin A is formed via degradation of erythromycin in acidic aqueous solutions in vitro as well as in vivo. Anhydroerythromycin A is active against S. aureus and B. cereus in vitro (MICs = 12.5 and 6.25 μg/ml, respectively). Anhydroerythromycin A also inhibits steroid 6β-hydroxylase activity associated with the cytochrome P450 (CYP) isoform CYP3A in human liver microsomes.
c[Arg-Arg-Arg-Arg-Dip-Dip-Dip] (Compound 8C) shows broad-spectrum activity against drug-resistant Gram-positive and Gram-negative bacteria, with MICs of 3.1, 3,1, 12.5, and 12.5 μg/mL for MRSA (ATCC BAA-1556), S. aureus (ATCC 29213), P. aeruginosa (ATCC 27883), and E. coli (ATCC 25922), respectively .
Gatifloxacin-d3 (hydrochloride) is the deuterium labeled Gatifloxacin (hydrochloride). Gatifloxacin hydrochloride (AM-1155; BMS-206584; PD135432) is a potent fluoroquinolone antibiotic with broad-spectrum antibacterial activity. Gatifloxacin hydrochloride inhibits bacterial type II topoisomerases (IC50=13.8 μg/ml for S. aureus topoisomerase IV) and E. coli DNA gyrase (IC50 = 0.109 μg/ml). Gatifloxacin hydrochloride can be used to treat bacterial conjunctivitis in vivo.
Suvratoxumab (MEDI4893) is a long-acting, high-affinity human anti-α-toxin monoclonal antibody (IgG1κ type). Suvratoxumab potently neutralizes α-toxin, a key S. aureus virulence factor. Suvratoxumab improves survival and reduces lung injury in an immunocompromised mice model of pneumonia. Suvratoxumab also enhances the antibacterial activity of Vancomycin (HY-B0671) or Linezolid (HY-10394) .
5-[(2-Nitrophenyl)methylene]-2,4-thiazolidinedione (Compound 4) has antimicrobial, anti-diabetic and antioxidant activities. 5-[(2-Nitrophenyl)methylene]-2,4-thiazolidinedione inhibits B. subtilis, S. aureus, K. pneumonia, E. coli, and S. typhi with MICs of 4.5-9.9 μΜ/mL, and inhibits A. niger and C. albicans with MICs of 4.99 μΜ/mL .
Longistyline A (Longistylin A) is a natural stilbene, it can be isolated from leaves of Cajanus cajan. Longistyline A shows antimicrobial activity against MRSA with an MIC value of 1.56 μg/mL. Longistyline A shows neuroprotective effects, it can be used for the research of infection and nerve diseases .
Antibacterial agent 105 (Compound 17) is a phenanthrolinic analog of quinolones show antibacterial activity against M. tuberculosis with antibacterial activity (MIC90=2.64 μM)。Antibacterial agent 105 exhibits antibacterial activities against different bacterial species with MIC90s of 11.18, 11.18,0.70,1.40,44.70, and 22.35 μM for M. smegmatis, M. aurum, M. marinum,BCG, E. aerogenes and S. aureus, respectively .
Antibacterial agent 189 (compound 3a) is a potent antimicrobial agent. Antibacterial agent 189 offers high binding energy against the target OMPA/exo-1,3-beta-glucanase proteins. Antibacterial agent 189 exhibits the potent antimicrobial activities against E. coli, P. aeruginosa, S. aureus, B. subtilis, C. Albicans and A. flavus. Antibacterial agent 189 shows high binding energy against target SMO and SUFU/GLI-1 proteins .
Micrococcin P1 is a macrocyclic peptide antibiotic and is a potent hepatitis C virus (HCV) inhibitor with an EC50 range of 0.1-0.5 μM . Micrococcin P1 has in vitro antibacterial activity against Gram-positive bacterial strains. The MIC values of Micrococcin P1 against S. aureus 1974149, E. faecalis 1674621 and S. pyogenes 1744264 are 2 μg/mL, 1 μg/mL and 1 μg/mL, respectively . Micrococcin P1 is also a potent inhibitor of the malaria parasitePlasmodium falciparum .
Antibacterial agent 106 (compound 8) is an orally active and potent antibacterial agent with antibiofilm activity. Antibacterial agent 106 shows potent antibacterial effect against multi-agent resistant (MDR)-Gram positive pathogens. Antibacterial agent 106 is highly effective in clearing 99.7% of the intracellular methicillin-resistant S. aureus (MRSA) harbored inside macrophages . Antibacterial agent 106 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
Citrullinated LL-37 1cit is a citrullinated LL-37 (HY-P1222) peptide. Citrullinated LL-37 1cit does not alter the antiviral effect of LL-37 toward human rhinovirus. Citrullinated LL-37 1cit shows antibacterial activity toward S. aureus. Citrullinated LL-37 1cit causes a reduction in the levels of IL-8, CCL5, and IL-6 mRNA induced by RV1B .
Deoxyshikonin increases the expression of VEGF-C and VEGF-A mRNA in HMVEC-dLy, promotes HIF-1α and HIF-1β subunit interaction and binds to specific DNA sequences targeted by HIF. Deoxyshikonin inhibited colorectal cancer (CRC) through the PI3K/Akt/mTOR pathway. Deoxyshikonin has proangiogenesis effect and antitumor activity. Deoxyshikonin is an antibacterial agent against methicillin-resistant S. aureus (MRSA) and S. pneumonia (MIC=17 μg/mL) .
Cochliodone A is an active compound extracted from cultures of the deep-sea derived fungus Chaetomium sp. and has antibacterial and anticancer activity. Cochliodone A is toxic to a variety of bacteria, with MICs of 15.3 μg/mL (V. vulnificus), 32.7 μg/mL (V. rotiferianus), 15.9 μg/mL (S. aureus ATCC 43300), and 16.3 μg/mL (S . aureus CGMCC 1.12409). Cochliodone A also inhibits a variety of cancer cell lines, with IC50s of 28.1 μM (A549), 20.7 μM (HeLa), and 23.2 μM (Hep G2) .
Pisiferic acid is an antibacterial agent with inhibitory activity against Gram-negative/positive bacteria such as P. vulgaris, S. aureus and B. subtilis. Pisiferic acid can be used to study bacterial infections .
XT-1 is an antimicrobial peptide derived from skin secretions of Xenopus tropicalis. XT-1 has strong activity against S.aureus, E.coli and C.albicans, the vaule of MIC are 5, 6, 50 μM , respectively .
MCF is an antimicrobial peptide derived from bee venom. MCF has activity against E.coli W 160-37, S.aureus 8530 and B.subtilis, the MIC values are 35-45 μg/ml, 25-35 μg/ml and 15-25 μg/ml .
Bovine tracheal antimicrobial peptide is a kind of comes from the tracheal mucosa of antimicrobial peptides. Bovine tracheal antimicrobial peptide has activity against E.coli D31, K.pneumoniae 13883, S.aureus 25923, P.aeruginosa 27853 and C.albicans 14053, MIC value 12-25, 12-25, 25-50, 25-50, 6-12 μg/ml, respectively .
ASP-1 is a strong antistaphylococcal peptide with minimum inhibitory concentrations (MICs) of the purified peptide against S. aureus and methicillin-resistant S. aureus (MRSA) ranged from 2 μg/mL to 64 μg/mL .
SYNV-cyclo(CGGYF) is a Staphylococcus hominis (S. hominis) C5 autoinducing peptide. SYNV-cyclo(CGGYF) inhibits S. aureus activity. SYNV-cyclo(CGGYF) has the potential for the research of S. aureus-mediated epithelial damage and inflammation .
SYNV-cyclo(CGGYF) TFA is a Staphylococcus hominis (S. hominis) C5 autoinducing peptide. SYNV-cyclo(CGGYF) TFA inhibits S. aureus activity. SYNV-cyclo(CGGYF) TFA has the potential for the research of S. aureus-mediated epithelial damage and inflammation .
Lugdunin is an antibiotic peptide. Lugdunin inhibits bacteria by dissipating their membrane potential. Lugdunin is active against Gram-positive bacteria, such as S. aureus, and reduces S. aureus skin and nasal colonization. Lugdunin induces LL-37 and CXCL8/MIP-2 in human keratinocytes and mouse skin .
Polistes mastoparan is an antimicrobial peptide. Polistes mastoparan increases S. aureus cell K + efflux and inhibits cell viability with EC50 of 5 μM .
Maximin 41 is an antimicrobial peptide. Maximin 41 has antibacterial activity against S. aureus (MIC: 75 μg/mL). Maximin 41 has hemolytic activities against human red cells .
Maximin 42 is an antimicrobial peptide. Maximin 42 has antibacterial activity against S. aureus (MIC: 37.5 μg/mL). Maximin 42 has hemolytic activities against human red cells .
Maximin 77 is an antimicrobial peptide. Maximin 77 has antibacterial activity against S. aureus (MIC: 18.8 μg/mL). Maximin 77 has hemolytic activities against human red cells .
Maximin 49 is an antimicrobial peptide. Maximin 49 has antibacterial activity against S. aureus (MIC: 18.8 μg/mL). Maximin 49 has hemolytic activities against human and rabbit red cells .
Aureusimine B (Phevalin) is a cyclic dipeptide. Aureusimine B can be produced by Staphylococcus aureus biofilms. Aureusimine B may be exploited as potential biomarker and/or therapeutic target for chronic, S. aureus biofilm-based infections .
Melimine is a hybrid antimicrobial peptide of Melittin (HY-P0233) and Protamine. Melimine is active against P. aeruginosa and S. aureus. Melimine has broad spectrum activity against bacteria, fungi and protozoa .
Im5, an antimicrobial peptide, has antibacterial (MIC: 10, 2.5-5, 0.5-1 μM for E. coli, S. aureus, B. subtilis respectively) and hemolytic activity (EC50: 28 μM) .
GP-2B is an antimicrobial peptide. GP-2B shows antibacterial activity against Gram-positive strain (MIC: 8-128 μg/mL for S. aureus and Enterococcus faecalis) .
cPcAMP1/26 is an antimicrobial peptide. cPcAMP1/26 effectively kills A.hydrophila and S. aureus. cPcAMP1/26 induces depolarization of the bacterial plasma membrane, and increases intracellular ROS levels .
PP102 is an antimicrobial peptide is active against gram-positive B. subtilis (MIC: 25 uM), S. aureus (MIC: 13.3 uM), S. lutea (MIC: 63 uM), and B. pumilu (MIC: 23 uM) .
Aurein 2.6 is an antibiotic antimicrobial peptide. Aurein 2.6 is active against Gram-positive bacterial (MIC: 25, 25, 30, 25, 30 μM for M. luteus, S. aureus, S. epidermis, S. mutans, B. subtilis) .
Aurein 3.1 is an antibiotic antimicrobial peptide. Aurein 2.6 is active against Gram-positive bacterial (MIC: 80, 50, 50, 50, 50 μM for M. luteus, S. aureus, S. epidermis, S. mutans, B. subtilis) .
Bombinin-BO1 is an antimicrobial peptide derived from toad Bombina orientalis skin secretions. Bombinin-BO1 is active against E. coli, S. aureus and Candida albicans, the MIC values are 64, 64, 128 mg/L, respectively .
Distinctin is an antimicrobial peptide. Distinctin can be isolated from frog skin. Distinctin has antibacterial activity against E. faecalis, P. aeruginosa, S. aureus and E. coli (MIC: 14.5, 28.0, 28.0, 14.5 μM) .
Maximin 45 is an antimicrobial peptide. Maximin 41 has antibacterial activity against S. aureus, E. coli, B. subtilis (MIC: 4.7, 9.4, 75 μg/mL). Maximin 45 has hemolytic activities against human and rabbit red cells .
Maximin 78 is an antimicrobial peptide. Maximin 78 has antibacterial activity against C. albicans, S. aureus, B. subtilis (MIC: 37.5, 4.7, 37.5 μg/mL). Maximin 78 has hemolytic activities against human and rabbit red cells .
TLN-58 is an antimicrobial peptide. TLN-58 has antibacterial activity against S. aureus, S. epidermidis, and group A Streptococcus. TLN-58 also induces inflammatory cytokine mRNAs upregulation in normal human keratinocytes and NCL-SG3 cells .
LA-Bac8c is a Lipoic acid modified antimicrobial peptide with enhanced antimicrobial properties. LA-Bac8c inhibits S. aureus, MRSA, S. epidermidis, E. coli, and P. aeruginosa with MICs of 1, 4, 8, 8, and 8 μg/mL .
Maximin H39 is an antimicrobial peptide. MaximinH39 has antibacterial activity against C. albicans, S. aureus, B. subtilis (MIC: 9.4, 9.4, 18.8 μg/mL). Maximin H39 has hemolytic activities against human and rabbit red cells .
MDP1, a Melittin-derived peptide, alters the integrity of both Gram-positive and Gram-negative bacterial membranes and kills the bacteria via membrane damages. MDP1 has a high-antibacterial activity against multidrug resistant (MDR) and reference strains of S. aureus, E. coli, and P. aeruginosa .
MDP1 acetate, a Melittin-derived peptide, alters the integrity of both Gram-positive and Gram-negative bacterial membranes and kills the bacteria via membrane damages. MDP1 acetate has a high-antibacterial activity against multidrug resistant (MDR) and reference strains of S. aureus, E. coli, and P. aeruginosa .
Amphomycin is a lipopeptide antibiotic that inhibits peptidoglycan synthesis and blocks cell wall development. Amphomycin exhibits potent antibacterial activities against methicillin-resistant S. aureus (MRSA), vancomycin-resistant enterococci (VRE), penicillin-gentamicin-erythromycin-resistant S. pneumonia, and linezolid-quinupristin-dalfopristin-resistant enterococci .
Maximin 68 is an antimicrobial peptide. Maximin 68 has antibacterial activity against C. albicans, S. aureus, E. coli, B. subtilis (MIC: 18.8, 9.4, 37.5, 9.4 μg/mL). Maximin 68 has hemolytic activities against human and rabbit red cells .
CysHHC10 is a synthetic antimicrobial peptide (AMP), and exhibits strong anti-microbial properties against both Gram-positive and Gram-negative bacteria. The MIC values of CysHHC10 against E. coli, P. aeruginosa, S. aureus and S. epidermidis are 10.1 mM, 20.2 mM, 2.5 mM and 1.3 mM, respectively .
PP113 is an antimicrobial peptide is active against Gram-negative and Gram-positive bacteria, E.coli (MIC: 73.3 uM), B. subtilis (MIC: 23.3 uM), S. aureus (MIC: 13 uM), S. lutea (MIC: 16.7 uM), and B. pumilu (MIC: 23.3 uM) .
CysHHC10 TFA is a synthetic antimicrobial peptide (AMP), and exhibits strong anti-microbial properties against both Gram-positive and Gram-negative bacteria. The MIC values of CysHHC10 TFA against E. coli, P. aeruginosa, S. aureus and S. epidermidis are 10.1 mM, 20.2 mM, 2.5 mM and 1.3 mM, respectively .
PP13 is an antimicrobial peptide, and is active against Gram-negative and Gram-positive bacteria E.coli (MIC: 16.7 uM), B. subtilis (MIC: 13.3 uM), S. aureus (MIC: 23.3 uM), S. lutea (MIC: 8.0 uM), and B. pumilu (MIC: 9.0 uM) .
Dermaseptin-B3 inhibits the growth of Gram-positive and Gram-negative bacteria (MIC: 1.3, 2.3, 5.0, 2.6, 2.3 μM for S. aureus, P. aeruginosa, P. aeruginosa, E. (ATCC 25922), E. (54127) respectively). Dermaseptin-B3 also inhibits tumor cell proliferation .
HG2 is a fast-acting antimicrobial peptide. HG2 shows anti-biofilm and anti-inflammatory activities. HG2 is active against Gram-positive pathogens, especially against MRSA strains (MIC: 16-32?μg/mL). HG2 can bind to bacterial lipids and reduces ATP concentration in S. aureus MRSA USA300 cells .
HG4 is a fast-acting antimicrobial peptide. HG4 shows anti-biofilm and anti-inflammatory activities. HG4 is active against Gram-positive pathogens, especially against MRSA strains (MIC: 32-64?μg/mL). HG4 can bind to bacterial lipids and reduces ATP concentration in S. aureus MRSA USA300 cells .
c[Arg-Arg-Arg-Arg-Nal-Nal-Nal] (Compound 9C) shows broad-spectrum activity against drug-resistant Gram-positive and Gram-negative bacteria, with MICs of 3.1, 3,1, 12.5, and 25 μg/mL for MRSA (ATCC BAA-1556), S. aureus (ATCC 29213), P. aeruginosa (ATCC 27883), and E. coli (ATCC 25922), respectively .
c[Arg-Arg-Arg-Arg-Dip-Dip-Dip] (Compound 8C) shows broad-spectrum activity against drug-resistant Gram-positive and Gram-negative bacteria, with MICs of 3.1, 3,1, 12.5, and 12.5 μg/mL for MRSA (ATCC BAA-1556), S. aureus (ATCC 29213), P. aeruginosa (ATCC 27883), and E. coli (ATCC 25922), respectively .
Citrullinated LL-37 1cit is a citrullinated LL-37 (HY-P1222) peptide. Citrullinated LL-37 1cit does not alter the antiviral effect of LL-37 toward human rhinovirus. Citrullinated LL-37 1cit shows antibacterial activity toward S. aureus. Citrullinated LL-37 1cit causes a reduction in the levels of IL-8, CCL5, and IL-6 mRNA induced by RV1B .
Omodenbamab is an anti-SpA (Staphylococcal protein A) human monoclonal antibody with a KD value of 0.0467 nM. Omodenbamab circumvents a key S. aureus evasion mechanism by targeting the cell wall moiety Protein A (SpA). Omodenbamab can be used in research of S. aureus bloodstream infection .
Tosatoxumab (AR-301; KBSA301) is a human immunoglobulin G1 monoclonal antibody that specifically neutralizes alpha-toxin (alpha-hemolysin; Hla) of S. aureus. Tosatoxumab binds to an N-terminal epitope of alpha-toxin, thereby preventing functional toxin pore oligomerisation. Tosatoxumab has the potential for passive immunotherapy in the S. aureus pneumonia as an adjunctive therapy to standard antibiotic agent .
Pagibaximab is a chimeric IgG1 antibody recognizing the surface component lipoteichoic acid of S. aureus and S. epidermidis. Pagibaximab can be used to prevent staphylococcal sepsis .
Suvratoxumab (MEDI4893) is a long-acting, high-affinity human anti-α-toxin monoclonal antibody (IgG1κ type). Suvratoxumab potently neutralizes α-toxin, a key S. aureus virulence factor. Suvratoxumab improves survival and reduces lung injury in an immunocompromised mice model of pneumonia. Suvratoxumab also enhances the antibacterial activity of Vancomycin (HY-B0671) or Linezolid (HY-10394) .
Lauric acid is a middle chain-free fatty acid with strong bactericidal properties. The EC50s for P. acnes, S.aureus, S. epidermidis, are 2, 6, 4 μg/mL, respectively .
Tenuigenin is a major active component isolated from the root of the Chinese herb Polygala tenuifolia. Tenuigenin protects against S.aureus-induced pneumonia by inhibiting NF-κB activation. Tenuigenin has anti-inflammatory effect .
Secologanin dimethyl acetal (Compound Ⅱ) is an iridoid glucoside that can be isolated from Pterocephalus perennis. Secologanin dimethyl acetal shows antimicrobial activity against S.aureus and S.epidermidi .
Lauric acid (Standard) is the analytical standard of Lauric acid. This product is intended for research and analytical applications. Lauric acid is a middle chain-free fatty acid with strong bactericidal properties. The EC50s for P. acnes, S.aureus, S. epidermidis, are 2, 6, 4 μg/mL, respectively.
Lysionotin is a flavonoid isolated from Gesneriaceae family. Lysionotin efficiently inhibit α-Toxin (a pore-forming protein) expression and shows significant protection against S. aureus in vitro and in vivo. Lysionotin has the potential for the treatment of S. aureus induced pneumonia .
Corianin is a sesquiterpene lactone that can be isolated from the fruits of Coriaria ruscifolia. Corianin shows antibacterial activity against S. aureus and S. epidermis .
(3R)-7,4’-Dihydrohomoisoflavanone is a natural product with antibacterial activities against S. aureus and methicillin-resistant Staphylococcus aureus (MRSA) .
Stearyl glycyrrhetinate, a major component in licorice extract, has a MIC against S. aureus strains of more than 256 mg/L. Stearyl glycyrrhetinate has antibacterial effects .
Thiolopyrrolone A (compound 1) exhibits antibacterial activities against BCG, M. tuberculosis and S. aureus with minimum inhibitory concentrations (MIC) of 10, 10 and 100 μg/mL, respectively .
Ianthelliformisamine B diTFA is a bromotyrosine-derived antibacterial agent. Ianthelliformisamine B diTFA is against E. coli and S. aureus strains with MICs of 14.5 μM and 144.7 μM .
Maximin 41 is an antimicrobial peptide. Maximin 41 has antibacterial activity against S. aureus (MIC: 75 μg/mL). Maximin 41 has hemolytic activities against human red cells .
Maximin 42 is an antimicrobial peptide. Maximin 42 has antibacterial activity against S. aureus (MIC: 37.5 μg/mL). Maximin 42 has hemolytic activities against human red cells .
Maximin 77 is an antimicrobial peptide. Maximin 77 has antibacterial activity against S. aureus (MIC: 18.8 μg/mL). Maximin 77 has hemolytic activities against human red cells .
Maximin 49 is an antimicrobial peptide. Maximin 49 has antibacterial activity against S. aureus (MIC: 18.8 μg/mL). Maximin 49 has hemolytic activities against human and rabbit red cells .
Penicillin V Potassium (Phenoxymethylpenicillin potassium salt) is an orally active antibiotic. Penicillin V Potassium inhibits the growth of Streptococci, C. difficile and S. aureus. Penicillin V Potassium can be used for the research of otitis, sinusitis, pharyngitis and tonsillitis .
Aureusimine B (Phevalin) is a cyclic dipeptide. Aureusimine B can be produced by Staphylococcus aureus biofilms. Aureusimine B may be exploited as potential biomarker and/or therapeutic target for chronic, S. aureus biofilm-based infections .
GP-2B is an antimicrobial peptide. GP-2B shows antibacterial activity against Gram-positive strain (MIC: 8-128 μg/mL for S. aureus and Enterococcus faecalis) .
Lividomycin A is a broad-spectrum aminoglycoside antibiotic. Lividomycin A shows antimicrobial activity. Lividomycin A shows a positive protecting effect for the experimental infections in mice with several bacteria such as S. aureus, P. aeruginosa, Klebsiella pneumoniae and Escherichia coli .
2,5-Dihydroxybenzaldehyde (Gentisaldehyde) is a naturally occurring antimicrobial that inhibits the growth of Mycobacterium avium subsp. paratuberculosis. 2,5-Dihydroxybenzaldehyde is active against S. aureus strains with a MIC50 of 500 mg/L .
(-)-Corynoxidine is an acetylcholinesterase inhibitor with an IC50 value of 89.0 μM, isolated from the aerial parts of Corydalis speciosa .
(-)-Corynoxidine exhibits antibacterial activities against Staphylococcus aureus and methicillin-resistant S. aureus strains in different degrees .
Angustifoline, an alkaloid, can be isolated from Lupinus angustifolius L. alkaloid extract. Angustifoline exhibits antimicrobial activity. Angustifoline could have bacteriostatic effects against S. aureus, B. subtilis, E. coli, P. aeruginosa and B. thuringiensis .
Angustifoline hydrochloride, an alkaloid, can be isolated from Lupinus angustifolius L. alkaloid extract. Angustifoline hydrochloride exhibits antimicrobial activity. Angustifoline hydrochloride could have bacteriostatic effects against S. aureus, B. subtilis, E. coli, P. aeruginosa and B. thuringiensis .
Antibacterial synergist 2 (compound 27) is a biofilm inhibitor. Antibacterial synergist 2 shows inhibitory effects to S. enterica, S. aureus, P. aeruginosa and C. albicans. Antibacterial synergist 2 can be used for the research related to biofilm-forming pathogens .
Continentalic acid from Aralia continentalis has minimum inhibitory concentrations (MICs) of approximately 8-16 µg/mL against S. aureus, including the Methicillin (HY-121544) susceptible Staphylococcus aureus (MSSA) and Methicillin-resistant Staphylococcus aureus (MRSA) standard strains .
8-Hydroxy-9,10-diisobutyryloxythymol is a natural monoterpenoid with antibacterial properties. 8-Hydroxy-9,10-diisobutyryloxythymol against S. aureus, S. flexneri, and S. paratyphi-B with MIC values of 6.25 μg/mL .
Maximin 45 is an antimicrobial peptide. Maximin 41 has antibacterial activity against S. aureus, E. coli, B. subtilis (MIC: 4.7, 9.4, 75 μg/mL). Maximin 45 has hemolytic activities against human and rabbit red cells .
Epitaraxerol (compound 6) is a natural product isolated from the leaves of E. neriifolia. Epitaraxerol shows moderate antifungal activity against C. albicans and low antimicrobial activity against T. mentagrophytes, A. niger, S. aureus, E. coli, P. aeruginosa, and B. subtilis .
Maximin 78 is an antimicrobial peptide. Maximin 78 has antibacterial activity against C. albicans, S. aureus, B. subtilis (MIC: 37.5, 4.7, 37.5 μg/mL). Maximin 78 has hemolytic activities against human and rabbit red cells .
Maximin H39 is an antimicrobial peptide. MaximinH39 has antibacterial activity against C. albicans, S. aureus, B. subtilis (MIC: 9.4, 9.4, 18.8 μg/mL). Maximin H39 has hemolytic activities against human and rabbit red cells .
Galbinic acid (α-Acetylsalazinic acid), a lichen acid, shows antibacterial activities against the Gram-positive bacteria B. cereus, B. subtilis, and S. aureus (MICs=62.5, 62.5, 250 μg/ml, respectively). Galbinic acid inhibits the Gram-negative bacterium E. coli (MIC=125 μg/ml) .
Pristinamycin, produced by Streptomyces pristinaespiralis, is an orally active streptogramin-like antibiotic consisting of two chemically unrelated components: Pristinamycin I (PI) and Pristinamycin II (PII). Pristinamycin is highly active against many antibiotic-resistant pathogens, particularly Gram-positive bacteria, including Methicillin-resistant Staphylococcus aureus (MRSA), Vancomycin-resistant S. aureus (VRSA) and Enterococcus faecium (VREF) .
1,4, 6-trihydroxy-5-methoxy-7-prenylxanthone is an antimicrobial agent that can be isolated from the genus garcinia. 1,4, 6-trihydroxy-5-methoxy-7-prenylxanthone inhibits S. aureus and B. cereus with MIC values of 128 μg/mL and 200 μg/mL, respectively .
Pachybasin is a major metabolite from culture broth of endophytic coelomyceteous AFKR-18 fungus. Pachybasin showes antimicrobial activities against E. coli, B. subtilis, M. luteus, S. cerevisiae, C. albicans, A. niger, and A. flavus, with MIC values of 64.0 μg/mL, and against S. aureus and F. oxysporum with MIC values of 32.0 and 16.0 μg/mL respectively .
2',3'-Dehydrosalannol is a potent antibacterial agent. 2',3'-Dehydrosalannol shows antibacterial activity against K. pneumonia ATCC 13883, P. aeruginosa ATCC 27853, S. aureus ATCC 25922, E. coli ATCC 11775, and E. faecalis ATCC 10541, with MIC values of 0.78, 1.56, 1.56, 6.25, and 25 µg/mL, respectively .
Anhydroerythromycin A is a degradation product of the macrolide antibiotic erythromycin. Anhydroerythromycin A is formed via degradation of erythromycin in acidic aqueous solutions in vitro as well as in vivo. Anhydroerythromycin A is active against S. aureus and B. cereus in vitro (MICs = 12.5 and 6.25 μg/ml, respectively). Anhydroerythromycin A also inhibits steroid 6β-hydroxylase activity associated with the cytochrome P450 (CYP) isoform CYP3A in human liver microsomes.
Longistyline A (Longistylin A) is a natural stilbene, it can be isolated from leaves of Cajanus cajan. Longistyline A shows antimicrobial activity against MRSA with an MIC value of 1.56 μg/mL. Longistyline A shows neuroprotective effects, it can be used for the research of infection and nerve diseases .
Deoxyshikonin increases the expression of VEGF-C and VEGF-A mRNA in HMVEC-dLy, promotes HIF-1α and HIF-1β subunit interaction and binds to specific DNA sequences targeted by HIF. Deoxyshikonin inhibited colorectal cancer (CRC) through the PI3K/Akt/mTOR pathway. Deoxyshikonin has proangiogenesis effect and antitumor activity. Deoxyshikonin is an antibacterial agent against methicillin-resistant S. aureus (MRSA) and S. pneumonia (MIC=17 μg/mL) .
Cochliodone A is an active compound extracted from cultures of the deep-sea derived fungus Chaetomium sp. and has antibacterial and anticancer activity. Cochliodone A is toxic to a variety of bacteria, with MICs of 15.3 μg/mL (V. vulnificus), 32.7 μg/mL (V. rotiferianus), 15.9 μg/mL (S. aureus ATCC 43300), and 16.3 μg/mL (S . aureus CGMCC 1.12409). Cochliodone A also inhibits a variety of cancer cell lines, with IC50s of 28.1 μM (A549), 20.7 μM (HeLa), and 23.2 μM (Hep G2) .
Enterotoxins (ETAs) trigger host immune system activation by binding to major histocompatibility complex class II and T-cell receptor (TCR) molecules. This interaction triggers a cascade of cell activation, cytokine production and migration, primarily mediated by Alphata T cells, affecting lung tissue and airways. Enterotoxin type A Protein, S. aureus (His) is the recombinant Staphylococcus aureus-derived Enterotoxin type A protein, expressed by E. coli , with N-6*His labeled tag. The total length of Enterotoxin type A Protein, S. aureus (His) is 233 a.a., with molecular weight of ~28 kDa.
Staphylokinase Protein efficiently converts plasminogen into active plasmin, a key enzyme in fibrinolysis. It forms a 1:1 complex with plasmin, activating additional plasminogen molecules and amplifying the fibrinolytic cascade. Staphylokinase Protein, S. aureus is the recombinant Staphylococcus aureus-derived Staphylokinase protein, expressed by E. coli , with tag free. The total length of Staphylokinase Protein, S. aureus is 136 a.a., with molecular weight of ~15.6 kDa.
ENTE Proteinas are staphylococcal enterotoxins that activate the host immune system by binding to major histocompatibility complex class II and T-cell receptor (TCR) molecules. This interaction forms a ternary complex that activates T lymphocytes and induces the systemic release of proinflammatory cytokines. ENTE Protein, S. aureus (N-His) is the recombinant Staphylococcus aureus-derived ENTE protein, expressed by E. coli , with N-6*His labeled tag. The total length of ENTE Protein, S. aureus (N-His) is 230 a.a., with molecular weight of ~27 kDa.
ENTE Proteinas are staphylococcal enterotoxins that activate the host immune system by binding to major histocompatibility complex class II and T-cell receptor (TCR) molecules. This interaction forms a ternary complex that activates T lymphocytes and induces the systemic release of proinflammatory cytokines. ENTE Protein, S. aureus (Baculovirus, His) is the recombinant Staphylococcus aureus-derived ENTE protein, expressed by Sf9 insect cells , with N-6*His labeled tag. The total length of ENTE Protein, S. aureus (Baculovirus, His) is 230 a.a., with molecular weight of ~28.4 kDa.
The MecA protein plays a crucial role in cellular machinery by facilitating the recognition and targeting of unfolded and aggregated proteins, directing them to the ClpC protease or other proteins involved in proteolysis. The function of this protein is critical for the efficient removal and degradation of abnormal proteins, ensuring cellular homeostasis and preventing the accumulation of potentially harmful protein aggregates. MecA Protein, S. aureus (His-SUMO) is the recombinant Staphylococcus aureus-derived MecA protein, expressed by E. coli , with N-His, N-SUMO labeled tag. The total length of MecA Protein, S. aureus (His-SUMO) is 239 a.a., with molecular weight of ~44.3 kDa.
Enterotoxins (SEBs) activate the host immune system by binding raw molecules to major histocompatibility complex class II and T-cell receptor (TCR) molecules. The formation of the ternary complex triggers significant activation of T lymphocytes, leading to the systemic release of pro-inflammatory cytokines. Enterotoxin type B Protein, S. aureus (P.pastoris, His) is the recombinant Staphylococcus aureus-derived Enterotoxin type B protein, expressed by P. pastoris , with N-6*His labeled tag. The total length of Enterotoxin type B Protein, S. aureus (P.pastoris, His) is 239 a.a., with molecular weight of ~30.4 kDa.
Enterotoxins (ETAs) trigger host immune system activation by binding to major histocompatibility complex class II and T-cell receptor (TCR) molecules. This interaction triggers a cascade of cell activation, cytokine production and migration, primarily mediated by Alphata T cells, affecting lung tissue and airways. Enterotoxin type A Protein, S. aureus (Baculovirus, His-Myc) is the recombinant Staphylococcus aureus-derived Enterotoxin type A protein, expressed by Sf9 insect cells , with N-10*His, C-Myc labeled tag. The total length of Enterotoxin type A Protein, S. aureus (Baculovirus, His-Myc) is 233 a.a., with molecular weight of ~31.0 kDa.
Enterotoxin (ETH) activates the host immune system by binding as a raw molecule to major histocompatibility complex class II and T-cell receptor (TCR) molecules, specifically through its alpha domain, specifically TRAV27 . This interaction forms a ternary complex that activates a large number of T lymphocytes and triggers the widespread release of proinflammatory cytokines. Enterotoxin type H Protein, S. aureus (P.pastoris, His) is the recombinant Staphylococcus aureus-derived Enterotoxin type H protein, expressed by P. pastoris , with N-His labeled tag. The total length of Enterotoxin type H Protein, S. aureus (P.pastoris, His) is 217 a.a., with molecular weight of ~27.1 kDa.
Clumping factor B (ClfB) is a cell surface-associated protein implicated in virulence, playing a crucial role in bacterial pathogenicity by promoting bacterial attachment to both alpha- and beta-chains of human fibrinogen. Its significance lies in inducing the formation of bacterial clumps, a mechanism that contributes to the pathogenicity and virulence of the bacteria. Clumping factor B Protein, S. aureus (His) is the recombinant Staphylococcus aureus-derived Clumping factor B protein, expressed by E. coli , with N-His labeled tag. The total length of Clumping factor B Protein, S. aureus (His) is 498 a.a., with molecular weight of ~80 kDa.
Enterotoxin type C-2 (SEC2) activates the host immune system by binding the unprocessed molecule to major histocompatibility complex class II and T-cell receptor (TCR) molecules. This interaction forms a ternary complex that activates a large number of T lymphocytes and triggers the widespread release of proinflammatory cytokines. Enterotoxin type C-2 Protein, S. aureus is the recombinant Staphylococcus aureus-derived Enterotoxin type C-2 protein, expressed by E. coli , with tag free. The total length of Enterotoxin type C-2 Protein, S. aureus is 239 a.a., with molecular weight of ~27.6 kDa.
TSST-1 protein induces symptoms related to toxic shock syndrome. TSST-1 Protein, S. aureus (His-SUMO) is the recombinant Staphylococcus aureus-derived TSST-1 protein, expressed by E. coli , with N-His, N-SUMO labeled tag. The total length of TSST-1 Protein, S. aureus (His-SUMO) is 194 a.a., with molecular weight of ~37.9 kDa.
Chemotaxis Inhibitory Protein (CIP) strategically counters the host defense mechanisms, inhibiting reactions of human neutrophils and monocytes to complement anaphylatoxin C5a and fMLP. As a molecular sentinel, CIP directly engages with C5aR and FPR, obstructing calcium responses induced by C5a and fMLP. In this tactical intervention, CIP acts as a guardian, finessefully thwarting bacterium phagocytosis. Chemotaxis inhibitory Protein, S. aureus (P.pastoris, His) is the recombinant Staphylococcus aureus-derived Chemotaxis inhibitory protein, expressed by P. pastoris , with N-His labeled tag. The total length of Chemotaxis inhibitory Protein, S. aureus (P.pastoris, His) is 121 a.a., with molecular weight of ~16.1 kDa.
Enterotoxin type G Proteinas, a staphylococcal enterotoxin, is implicated in staphylococcal food poisoning syndrome, causing severe symptoms like high fever, hypotension, diarrhea, shock, and fatalities. Its ability to induce a range of adverse effects underscores its significance in foodborne illnesses, emphasizing the severity of impact on affected individuals. Enterotoxin type G Protein, S. aureus (His-SUMO) is the recombinant Staphylococcus aureus-derived Enterotoxin type G protein, expressed by E. coli , with N-His, N-SUMO labeled tag. The total length of Enterotoxin type G Protein, S. aureus (His-SUMO) is 233 a.a., with molecular weight of ~43.0 kDa.
Exfoliative toxin A protein, with serine protease-like properties, binds to skin protein profilaggrin, demonstrating cleavage activity after acidic residues. Its involvement is associated with impetigous diseases, particularly staphylococcal scalded skin syndrome (SSSS). Exfoliative toxin A Protein, S. aureus (His) is the recombinant Staphylococcus aureus-derived Exfoliative toxin A protein, expressed by E. coli , with N-6*His labeled tag. The total length of Exfoliative toxin A Protein, S. aureus (His) is 242 a.a., with molecular weight of ~30.9 kDa.
The alpha-hemolysin protein binds to eukaryotic cell membranes, triggering the release of low molecular weight molecules and causing osmotic lysis. It inhibits the chemotaxis of host neutrophils toward the diseased area. Alpha-hemolysin Protein, S. aureus (P.pastoris, His) is the recombinant Staphylococcus aureus-derived Alpha-hemolysin protein, expressed by P. pastoris , with N-6*His labeled tag. The total length of Alpha-hemolysin Protein, S. aureus (P.pastoris, His) is 293 a.a., with molecular weight of ~35.3 kDa.
Clumping factor A protein facilitates bacterial attachment to human fibrinogen gamma-chain, promoting the formation of bacterial clumps. It is a cell surface-associated protein and plays a role in bacterial virulence. Clumping factor A Protein, S. aureus (P.pastoris, His) is the recombinant Staphylococcus aureus-derived Clumping factor A protein, expressed by P. pastoris , with N-His labeled tag. The total length of Clumping factor A Protein, S. aureus (P.pastoris, His) is 331 a.a., with molecular weight of ~38.5 kDa.
Peptide deformylase, a crucial enzyme in protein biosynthesis, catalyzes the removal of the formyl group from the N-terminal methionine of newly synthesized proteins. Displaying broad specificity at positions beyond the N-terminal L-methionine, the enzyme ensures proper maturation and functionality of proteins, emphasizing its essential contribution to the intricate process of protein synthesis and modification. Peptide deformylase Protein, S. aureus (P.pastoris, His) is the recombinant Staphylococcus aureus-derived Peptide deformylase protein, expressed by P. pastoris , with N-6*His labeled tag. The total length of Peptide deformylase Protein, S. aureus (P.pastoris, His) is 183 a.a., with molecular weight of ~25 kDa.
Gamma-hemolysin component C (HLgC) acts as a toxin, forming cell membrane pores with hemolytic and leukotoxic activities. The toxicity of HlgC requires sequential binding and cooperative association with S- and F-class components to form heterooligomeric complexes. Gamma-hemolysin component C Protein, S. aureus (P.pastoris, His) is the recombinant Staphylococcus aureus-derived Gamma-hemolysin component C protein, expressed by P. pastoris , with N-His labeled tag. The total length of Gamma-hemolysin component C Protein, S. aureus (P.pastoris, His) is 286 a.a., with molecular weight of ~34.6 kDa.
Clustering factor A (ClfA) is a virulence-related cell surface-associated protein that plays a key role in bacterial pathogenicity. It promotes bacterial attachment exclusively to the gamma chain of human fibrinogen, demonstrating the specificity of its interaction with host proteins. Clumping factor A Protein, S. aureus is the recombinant Staphylococcus aureus-derived Clumping factor A protein, expressed by E. coli , with tag free. The total length of Clumping factor A Protein, S. aureus is 331 a.a., with molecular weight of ~36.1 kDa.
Leukocidin-F subunit/LukF protein induces cytotoxic changes in polymorphonuclear leukocytes, while gamma-hemolysin, with components H-gamma-I and H-gamma-II identical to F, causes hemolysis in red blood cells. These proteins collectively contribute to pathogenic mechanisms by exerting cytotoxic effects on immune cells and inducing hemolysis in red blood cells. Leukocidin-F subunit/LukF Protein, S. aureus (Myc, His-SUMO) is the recombinant Staphylococcus aureus-derived Leukocidin-F subunit/LukF protein, expressed by E. coli , with N-His, C-Myc, N-SUMO labeled tag. The total length of Leukocidin-F subunit/LukF Protein, S. aureus (Myc, His-SUMO) is 298 a.a., with molecular weight of ~54.0 kDa.
Staphopain B is a cysteine protease that severely disrupts host immunity by degrading elastin, fibrin, fibronectin, and kininogen. It blocks phagocytosis of opsonized Staphylococcus aureus and induces neutrophil and monocyte death through proteolytic activity. Staphopain B Protein, S. aureus (GST) is the recombinant Staphylococcus aureus-derived Staphopain B protein, expressed by E. coli , with N-GST labeled tag. The total length of Staphopain B Protein, S. aureus (GST) is 174 a.a., with molecular weight of ~46.9 kDa.
MCT/SACOL1244 Protein intricately participates in lipid metabolism, specifically playing a vital role in fatty acid biosynthesis. MCT/SACOL1244 Protein, S. aureus (P.pastoris, His) is the recombinant Staphylococcus aureus-derived MCT/SACOL1244 protein, expressed by P. pastoris , with N-6*His labeled tag. The total length of MCT/SACOL1244 Protein, S. aureus (P.pastoris, His) is 308 a.a., with molecular weight of ~35.6 kDa.
Gamma-hemolysin component B (HLgB) acts as a toxin, creating cell membrane pores with hemolytic and leukotoxic activities. Furthermore, HLgB promotes AMFR-mediated inflammation by promoting “Lys-27” linked ubiquitination of TAB3, mediating TAK1-TAB3 complex formation, and activating NF-kappa-B signaling. Gamma-hemolysin component B Protein, S. aureus (P.pastoris, His) is the recombinant Staphylococcus aureus-derived Gamma-hemolysin component B protein, expressed by P. pastoris , with N-His labeled tag. The total length of Gamma-hemolysin component B Protein, S. aureus (P.pastoris, His) is 300 a.a., with molecular weight of ~36.1 kDa.
Gamma-hemolysin component A (HLgA) functions as a toxin and creates cell membrane pores with hemolytic and leukotoxic activities. Its action depends on sequential binding and cooperative association with class S and class F components to form heterooligomeric complexes. Gamma-hemolysin component A Protein, S. aureus (Myc, His) is the recombinant Staphylococcus aureus-derived Gamma-hemolysin component A protein, expressed by E. coli , with N-His, C-Myc labeled tag. The total length of Gamma-hemolysin component A Protein, S. aureus (Myc, His) is 280 a.a., with molecular weight of ~39.4 kDa.
Lauric acid-d33 is the deuterium labeled Lauric acid. Lauric acid is a middle chain-free fatty acid with strong bactericidal properties. The EC50s for P. acnes, S.aureus, S. epidermidis, are 2, 6, 4 μg/mL, respectively.
Lauric acid-d233 is the deuterium labeled Lauric acid. Lauric acid is a middle chain-free fatty acid with strong bactericidal properties. The EC50s for P. acnes, S.aureus, S. epidermidis, are 2, 6, 4 μg/mL, respectively.
Lauric acid- 13C is the 13C labeled Lauric acid. Lauric acid is a middle chain-free fatty acid with strong bactericidal properties. The EC50s for P. acnes, S.aureus, S. epidermidis, are 2, 6, 4 μg/mL, respectively.
Lauric acid-d2 is the deuterium labeled Lauric acid. Lauric acid is a middle chain-free fatty acid with strong bactericidal properties. The EC50s for P. acnes, S.aureus, S. epidermidis, are 2, 6, 4 μg/mL, respectively.
Lauric acid-d5 is the deuterium labeled Lauric acid. Lauric acid is a middle chain-free fatty acid with strong bactericidal properties. The EC50s for P. acnes, S.aureus, S. epidermidis, are 2, 6, 4 μg/mL, respectively.
Lauric acid- 13C-1 is the deuterium labeled Lauric acid. Lauric acid is a middle chain-free fatty acid with strong bactericidal properties. The EC50s for P. acnes, S.aureus, S. epidermidis, are 2, 6, 4 μg/mL, respectively[1].
Iclaprim-d6 (AR-100-d6) is the deuterium labeled Iclaprim. Iclaprim is a new selective bacterial Dihydrofolate inhibitor, which can inhibit the growth of S. aureus (MRSA) with an MIC90 of 0.06 μg/mL.
Penicillin V- 13C6 (potassium) is the 13C6 labeled Penicillin V (potassium). Penicillin V Potassium (Phenoxymethylpenicillin potassium salt) is an orally active antibiotic. Penicillin V Potassium inhibits the growth of Streptococci, C. difficile and S. aureus. Penicillin V Potassium can be used for the research of otitis, sinusitis, pharyngitis and tonsillitis.
Penicillin V-d5 (Phenoxymethylpenicillin-d5) is the deuterium labeled Penicillin V. Penicillin V (Phenoxymethylpenicillin) is an orally active antibiotic. Penicillin V inhibits the growth of Streptococci, C. difficile and S. aureus. Penicillin V can be used for the research of otitis, sinusitis, pharyngitis and tonsillitis[1][2][3][4].
Penicillin V (Potassium)-d5 is the deuterium labeled Penicillin V Potassium[1]. Penicillin V Potassium (Phenoxymethylpenicillin potassium salt) is an orally active antibiotic. Penicillin V Potassium inhibits the growth of Streptococci, C. difficile and S. aureus. Penicillin V Potassium can be used for the research of otitis, sinusitis, pharyngitis and tonsillitis[2][3][4][5].
Gatifloxacin-d3 (hydrochloride) is the deuterium labeled Gatifloxacin (hydrochloride). Gatifloxacin hydrochloride (AM-1155; BMS-206584; PD135432) is a potent fluoroquinolone antibiotic with broad-spectrum antibacterial activity. Gatifloxacin hydrochloride inhibits bacterial type II topoisomerases (IC50=13.8 μg/ml for S. aureus topoisomerase IV) and E. coli DNA gyrase (IC50 = 0.109 μg/ml). Gatifloxacin hydrochloride can be used to treat bacterial conjunctivitis in vivo.
Inquiry Online
Your information is safe with us. * Required Fields.